Myasthenia gravis in association with allogeneic bone marrow transplantation: clinical observations, therapeutic implications and review of literature.

Abstract:

:Myasthenia gravis (MG) is a rare complication of allogeneic bone marrow transplantation (BMT). We present the 11th case in the medical literature, a 23-year-old female 100 months post-allogeneic bone marrow transplantation for acute myelogenous leukemia (AML). After discontinuation of immunosuppression for chronic graft-versus-host disease (GVHD) involving skin, gastrointestinal tract and lacrimal glands, the patient developed severe, progressive dysphagia initially attributed to esophageal candidiasis. With the development of muscle weakness, ptosis, and dysphonia the diagnosis of generalized myasthenia gravis was suspected, and confirmed by elevated anti-acetylcholine receptor antibody titer and a positive edrophonium challenge. Prednisone and pyridostigmine produced improvement, and thymectomy was performed without pathologic evidence of thymoma. Recurrent post-operative respiratory distress required transient mechanical ventilation. Twenty-seven months after diagnosis, the patient requires maintenance prednisone to control symptoms of myasthenia gravis. The clinical features of all reported cases of MG post-allogeneic BMT are reviewed, and universal features include an association with decreasing immunosuppression, the presence of other manifestations of chronic GVHD, anti-acetylcholine receptor antibodies, and the absence of an associated thymoma. HLA Cw1, Cw7 and DR2 were identified at frequencies significantly above that expected from HLA antigen prevalance studies, and may be markers for increased risk of developing MG post-allogeneic BMT. No statistically significant associations with HLA A2, B7, B35 or donor-recipient sex mismatch were present. Reinstitution of immunosuppression and standard therapies for myasthenia gravis were effective in the majority of cases. The role of thymectomy in this population remains unclear.

journal_name

Bone Marrow Transplant

authors

Mackey JR,Desai S,Larratt L,Cwik V,Nabholtz JM

doi

10.1038/sj.bmt.1700759

subject

Has Abstract

pub_date

1997-05-01 00:00:00

pages

939-42

issue

9

eissn

0268-3369

issn

1476-5365

journal_volume

19

pub_type

杂志文章
  • Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC.

    abstract::We investigate the feasibility of CD34-selected peripheral blood stem cell (PBSC) transplantation followed by pre-emptive CD8-depleted donor lymphocyte infusions (DLI) after a minimal conditioning regimen. Six patients with advanced hematological malignancies ineligible for a conventional myeloablative transplant (n=5...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1704220

    authors: Baron F,Baudoux E,Frère P,Tourqui S,Schaaf-Lafontaine N,Herens C,DePrijck B,Fillet G,Beguin Y

    更新日期:2003-10-01 00:00:00

  • Unusual recurrence of chronic myelogenous leukemia following bone marrow transplantation.

    abstract::We report a patient who developed a bone and adjacent soft tissue malignancy 22 months after bone marrow transplantation (BMT) for Philadelphia chromosome positive chronic myelogenous leukemia (CML). Concomitant bone marrow was cytologically and cytogenetically normal. Cytogenetic study of tumoral tissue was unsuccess...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Millot F,Facon T,Kerckaert JP,Fenaux P,Lai JL,Parent M,Bauters F,Jouet JP

    更新日期:1991-05-01 00:00:00

  • Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells.

    abstract::Among the drugs used in conditioning regimens for stem cell transplantation, high-dose melphalan (HDM) plays an important role for both its strong myeloablative effect and for its favourable dose-response ratio. Here we report five cases of high frequency atrial fibrillation (AF) developing after HDM. Duration of the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701217

    authors: Olivieri A,Corvatta L,Montanari M,Brunori M,Offidani M,Ferretti GF,Centanni M,Leoni P

    更新日期:1998-05-01 00:00:00

  • Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse.

    abstract::Large registry studies have shown superior disease-free survival (DFS) with matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT) over chemotherapy alone for patients with B-precursor acute lymphoblastic leukemia (ALL) and a late BM relapse. As most of these patients will not have an MSD...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.217

    authors: Beck JC,Cao Q,Trotz B,Smith AR,Weigel BJ,Verneris MR,Burke MJ

    更新日期:2011-07-01 00:00:00

  • Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor.

    abstract::One hundred and one donors who had received filgrastim (rhG-CSF) for the purpose of donating either granulocytes or peripheral blood stem cells (PBSC) for their relatives more than 3 years ago were contacted. All donors had received daily rhG-CSF at a median dose of 16 microg/kg/day (range 3-16) for a median of 6 days...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702072

    authors: Cavallaro AM,Lilleby K,Majolino I,Storb R,Appelbaum FR,Rowley SD,Bensinger WI

    更新日期:2000-01-01 00:00:00

  • Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT.

    abstract::During the past few years major progress has been made in the diagnosis and therapy of CMV infection after allogeneic BMT. The aim of this survey was to investigate the use of diagnostic techniques, use of prophylaxis and the therapeutic strategies among members of the EBMT. Seventy centers from 20 countries responded...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Ljungman P,De Bock R,Cordonnier C,Einsele H,Engelhard D,Grundy J,Locasciulli A,Reusser P,Ribaud P

    更新日期:1993-10-01 00:00:00

  • Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study.

    abstract::In order to identify cytomegalovirus (CMV)-seropositive patients who are at risk of developing CMV infection following first allogeneic hematopoietic cell transplantation (allo-HCT), we built up a scoring system based on patient/donor characteristics and transplantation modalities. To this end, 3690 consecutive patien...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01178-6

    authors: Beauvais D,Drumez E,Blaise D,Peffault de Latour R,Forcade E,Ceballos P,Uyttebroeck A,Labussière H,Nguyen S,Bourhis JH,Chevallier P,Thiebaut A,Poiré X,Maury S,Deconinck E,Cluzeau T,Brissot E,Huynh A,Rubio MT,Duhamel

    更新日期:2020-12-18 00:00:00

  • Feasibility and timing of unrelated donor identification for patients with ALL.

    abstract::Patients with relapsed ALL frequently have short duration second or later remissions, leaving only a brief window of time when it is possible to perform BMT. When no sibling donor is available, identifying and unrelated donor in a timely fashion can be difficult while autologous BMT (ABMT) can be performed more quickl...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Davies SM,Ramsay NK,Weisdorf DJ

    更新日期:1996-05-01 00:00:00

  • Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD.

    abstract::The efficacy of posttransplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG) in controlling GVHD has been previously reported. We aim to study the safety and efficacy of the use of dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning regimen allo-HSCT in 270 patients w...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0813-9

    authors: Salas MQ,Prem S,Atenafu EG,Datt Law A,Lam W,Al-Shaibani Z,Loach D,Kim DDH,Michelis FV,Lipton JH,Kumar R,Mattsson J,Viswabandya A

    更新日期:2020-09-01 00:00:00

  • Complete heart block in association with graft-versus-host disease.

    abstract::An infant who received haploidentical BM for severe combined immunodeficiency (SCID) developed acute, reversible complete heart block in association with an exacerbation of GVHD. Respiratory distress and myocardial dysfunction were also seen with this and previous GVHD exacerbations. The patient had not received chemo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701038

    authors: Gilman AL,Kooy NW,Atkins DL,Ballas Z,Rumelhart S,Holida M,Lee N,Goldman F

    更新日期:1998-01-01 00:00:00

  • High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.

    abstract::Forty-eight adult patients with recurrent or refractory intermediate grade or immunoblastic lymphoma received high-dose carmustine (BCNU), etoposide, Ara C and cyclophosphamide (BEAC), followed by autologous bone marrow transplantation (BMT). Median follow-up is 906 days (range 613-2067 days). The complete remission r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: van Besien K,Tabocoff J,Rodriguez M,Andersson B,Mehra R,Przepiorka D,Dimopoulos M,Giralt S,Suki S,Khouri I

    更新日期:1995-04-01 00:00:00

  • Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD.

    abstract::Budesonide (BUD) is a steroid with a low bioavailability, which has been used for the treatment of oral manifestations of chronic GVHD (cGVHD). We retrospectively evaluated the efficacy of BUD in the treatment of gastrointestinal cGVHD. Thirteen patients (median age 47 years) receiving BUD for the treatment of cGVHD a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.209

    authors: Andree H,Hilgendorf I,Leithaeuser M,Junghanss C,Holzhueter S,Loddenkemper C,Steiner B,Freund M,Wolff D

    更新日期:2008-10-01 00:00:00

  • Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion.

    abstract::In this study, cytogenetic and molecular analyses were employed to assess the response to therapy in 29 chronic myeloid leukemia patients undergoing high dose chemotherapy followed by autologous stem cell infusion. Of these, 11 had previously achieved hematologic remission and cytogenetic improvement after alpha-2b in...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Lo Coco F,Mandelli F,Diverio D,Alimena G,De Fabritiis P,Meloni G,Cedrone M,Frontani M,Guerrasio A,Saglio G

    更新日期:1990-10-01 00:00:00

  • Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: late complications of therapy.

    abstract::Treatment of autoimmune disease with bone marrow transplantation (BMT) is under investigation. A few reports of patients undergoing allogeneic BMT for malignant conditions observed the resolution of psoriasis after BMT, with minimal late morbidity. We describe a patient with chronic myelogenous leukemia (CML) whose ps...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702703

    authors: Adkins DR,Abidi MH,Brown RA,Khoury H,Goodnough LT,Vij R,Westervelt P,DiPersio JF

    更新日期:2000-12-01 00:00:00

  • Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy.

    abstract::We present 60 patients with refractory (n=8) or relapsed (n=52) adult ALL who received allogeneic hematopoietic SCT (HSCT) with (n=41) or without (n=19) prior reinduction chemotherapy. In our center, omission of reinduction is recommended if a suitable donor is promptly available, tumor burden is moderate and disease ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.258

    authors: Terwey TH,Massenkeil G,Tamm I,Hemmati PG,Neuburger S,Martus P,Dörken B,Hoelzer D,Arnold R

    更新日期:2008-12-01 00:00:00

  • Low bone mineral density is associated with insulin resistance in bone marrow transplant subjects.

    abstract::Post-BMT subjects have an increased bone fracture risk. Additionally, several factors were associated with osteopenia and osteoporosis in these individuals. We aimed to identify other factors associated with osteopenia and osteoporosis in allogeneic post-BMT subjects. We conducted a cross-sectional study with 47 allog...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.70

    authors: Faulhaber GA,Premaor MO,Moser Filho HL,Silla LM,Furlanetto TW

    更新日期:2009-06-01 00:00:00

  • High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.

    abstract::Eighteen patients with chronic myelogenous leukemia (CML) in chronic (9 patients) or advanced phases (9 patients) underwent autologous bone marrow transplantation (BMT) with a preparative regimen using high doses of cyclophosphamide, etoposide and total body irradiation (CY-VP16-TBI): cyclophosphamide 60 mg/kg daily o...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Kantarjian HM,Talpaz M,Andersson B,Khouri I,Giralt S,Rios MB,Champlin R,Hester J,Deisseroth AB

    更新日期:1994-07-01 00:00:00

  • The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia.

    abstract::The role of various cell subpopulations involved in the graft-versus-leukemia (GVL) effect induced by allogeneic bone marrow transplantation (BMT) was investigated in (BALB/c x C57BL/6)F1 (F1) recipients, inoculated with murine B cell leukemia (BCL1), by using monoclonal murine anti-IL-2 receptor antibodies or rabbit ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Weiss L,Reich S,Slavin S

    更新日期:1995-09-01 00:00:00

  • A comparison of serological, cellular and DNA-RFLP methods for HLA matching in the selection of related bone marrow donors.

    abstract::Serological, cellular and DNA-RFLP (restriction fragment length polymorphism) methods of determining HLA compatibility between 10 leukaemic patients and potential related bone marrow donors were systematically compared. DR beta/DQ alpha/DQ beta/DNA-RFLP typing of these families gave results in agreement with those obt...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Howell WM,Evans PR,Spellerberg MB,Wilson PJ,Smith JL

    更新日期:1989-01-01 00:00:00

  • Low incidence of hemorrhagic cystitis following ex vivo T-cell depleted haploidentical hematopoietic cell transplantation in children.

    abstract::Hemorrhagic cystitis (HC) is a debilitating complication following allogenic hematopoietic cell transplantation (HCT). HLA disparity and T-cell depletion have been implicated as risk factors for HC. However, reports on the incidence and risk factors for HC in ex vivo T-cell depleted haploidentical HCT (haploHCT) in ch...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0672-4

    authors: Jepsen C,Turkiewicz D,Ifversen M,Heilmann C,Toporski J,Dykes J,Mellgren K,Pronk CJ

    更新日期:2020-01-01 00:00:00

  • Return of immunohematopoietic impairment a long time after murine syngeneic bone marrow transplantation.

    abstract::We have tested the immunologic status and hematologic parameters of mice 2 months (short-term survivors) or 18 months (long-term survivors) after lethal total body irradiation and syngeneic bone marrow transplantation (SBMT), and of normal mice of corresponding age. Long-term SBMT survivors showed significantly lowere...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Skórski T,Kawalec M,Ratajczak M,Szczylik C,Kawiak J

    更新日期:1990-11-01 00:00:00

  • Childhood to adult transition and long-term follow-up after blood and marrow transplantation.

    abstract::The use of hematopoietic stem cell transplantation or blood and marrow transplantation (BMT) is on the increase worldwide. With BMT's increasing utilization and increasing success, the number of BMT survivors in the United States alone is expected to surpass 500 000 by the year 2030. BMT survivors are susceptible to a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.228

    authors: Cupit MC,Duncan C,Savani BN,Hashmi SK

    更新日期:2016-02-01 00:00:00

  • Growth, growth hormone and final height after BMT. Possible recovery of irradiation-induced growth hormone insufficiency.

    abstract::The aim of the present study was to assess growth, final height, growth hormone (GH) secretion and growth factors after BMT including TBI in childhood. The median age of the 25 participants was 11.3 years at BMT, and a median of 7.5 years had elapsed since BMT. The median height standard deviation score (SDS) declined...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Holm K,Nysom K,Rasmussen MH,Hertz H,Jacobsen N,Skakkebaek NE,Krabbe S,Müller J

    更新日期:1996-07-01 00:00:00

  • Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants?

    abstract::Approaches to determine whether one transplant-related therapy is better than another include: (1) using experimental data, such as those from randomized controlled trials (RCTs); (2) using observational data, such as those from observational databases (ODBs) and (3) using conclusions from the structured quantificatio...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.447

    authors: Gale RP,Eapen M,Logan B,Zhang MJ,Lazarus HM

    更新日期:2009-03-01 00:00:00

  • Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate.

    abstract::Severe veno-occlusive disease (VOD), characterised by elevated serum bilirubin levels, is a known complication in the first 3 weeks after peripheral blood stem cell transplantation (PBSCT). Severe VOD is associated with capillary leakage and multiple organ dysfunction and leads to high mortality. We report a 17-year-o...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701211

    authors: Heying R,Nürnberger W,Spiekerkötter U,Göbel U

    更新日期:1998-05-01 00:00:00

  • Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.

    abstract::High-dose chemotherapy (HDC) was investigated in high-risk neuroblastoma (HR-NBL) to reduce the risk of relapse. We report the results of the 30-year experience of a cohort of patients with HR-NBL treated with high-dose (HD) busulfan (Bu)-containing regimens. From 1980 to 2009, 215 patients aged >1 year with stage 4 N...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2016.75

    authors: Proust-Houdemont S,Pasqualini C,Blanchard P,Dufour C,Benhamou E,Goma G,Semeraro M,Raquin MA,Hartmann O,Valteau-Couanet D

    更新日期:2016-08-01 00:00:00

  • Autografting in Philadelphia (Ph)+ chronic myeloid leukaemia using cultured marrow: an update of a pilot study.

    abstract::Incubation of CML marrow in long-term culture (LTC) conditions may result in selection of normal (Ph-) LTC-initiating cells (LTC-IC) as early as 10 days, and in production of Ph- clonogenic cells and mature end cells within 5 weeks. This was the rationale for using marrow cells from 10-day-old LTC to autograft nine ch...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700777

    authors: Coutinho LH,Chang J,Brereton ML,Morgenstern GR,Scarffe JH,Harrison CJ,Yin JA,Darbyshire PJ,Burdach S,Dexter TM,Testa NG

    更新日期:1997-05-01 00:00:00

  • Follow-up of chimerism in children with hematological diseases after allogeneic hematopoietic progenitor cell transplants.

    abstract::Using in situ hybridization with an X and Y chromosome probe mixture, 106 bone marrow samples from 38 patients with malignant and non-malignant hematological diseases who received sex-mismatched allogeneic hematopoietic progenitor cell transplants (PCT) in a single institution within short-term intervals (1, 3, 6, 12,...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701816

    authors: Ortega M,Escudero T,Caballín MR,Olivé T,Ortega JJ,Coll MD

    更新日期:1999-07-01 00:00:00

  • Portal vein thrombosis after hematopoietic cell transplantation: frequency, treatment and outcome.

    abstract::Patients who develop veno-occlusive disease (VOD) of the liver may have low plasma levels of the natural anticoagulants protein C and antithrombin III, but large vessel thromboses are not commonly reported in these patients. We reviewed the records of 1847 consecutive patients for evidence of portal vein thrombosis. E...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703368

    authors: Kikuchi K,Rudolph R,Murakami C,Kowdley K,McDonald GB

    更新日期:2002-02-01 00:00:00

  • Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation.

    abstract::Allo-SCT using unrelated donors is a curative treatment for patients with hematological disorders. The best donor is one matched for 10/10 HLA alleles, however studies have shown an additional survival benefit when considering other genetic factors. It has been shown that a six-nucleotide insertion/deletion polymorphi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2014.238

    authors: Shaw BE,Lee F,Krishnamurthy S,Byrne JL,Seedhouse C,Mayor NP,Maldonado-Torres H,Saudemont A,Marsh SG,Madrigal JA,Russell NH

    更新日期:2015-02-01 00:00:00